Takashi Kasai

6PUBLICATIONS
9CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 20, 2023
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.

Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda

|May 25, 2023
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.

Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura

|Oct 14, 2022
Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.

Takashi Kasai, Kiyoshi Mori, Tomohide Sugiyama

|Aug 20, 2021
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.

Hisao Imai, Takayuki Kishikawa, Hiroyuki Minemura

|Nov 02, 2020
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.

Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi

|Feb 16, 2020
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.

Takashi Kasai, Kiyoshi Mori, Kazuma Kishi

Pageof 1

Frequent Collaborators

3 joint publications

Hisao Imai

2 joint publications

Takayuki Kishikawa

2 joint publications

Hiroyuki Minemura

2 joint publications

Yutaka Yamada